Related Experiment Videos

Response to: 'Differentiating disease activity from damage in systemic sclerosis: it's still early days!' by Jain and

Mandana Nikpour¹,

¹Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia m.nikpour@unimelb.edu.au.

Annals of the Rheumatic Diseases

|May 24, 2019

Abstract

No abstract available in PubMed .

Keywords:

disease activity systemic sclerosis treatment

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Early detection, treatment initiation, and long-term health outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic literature review and expert consensus.

Modern rheumatology·2026

Longitudinal comparison of treat-to-target states and clinical outcomes in patients with late-onset versus early-onset systemic lupus erythematosus.

The Journal of rheumatology·2026

High disease activity persists in adults with childhood-onset lupus.

Lupus science & medicine·2026

High levels of vascular cell adhesion molecule-1 associate with a 'vasculopathic' phenotype in systemic sclerosis with higher mortality.

Rheumatology (Oxford, England)·2026

Predictive Accuracy of Serum N-Terminal Pro-B-Type Natriuretic Peptide Alone and in Combination with Respiratory Function Tests to Identify Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).

Diagnostics (Basel, Switzerland)·2026

Modeling Systemic Lupus Erythematosus Treatment Cost-Effectiveness Based on a Novel Lupus Low Disease Activity State Treat-to-Target Approach.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

See all related articles